Kymera Therapeutics, Inc. $KYMR Position Boosted by Capital Research Global Investors

Capital Research Global Investors grew its holdings in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 23.7% in the 4th quarter, HoldingsChannel.com reports. The firm owned 1,560,791 shares of the company’s stock after purchasing an additional 298,609 shares during the period. Capital Research Global Investors’ holdings in Kymera Therapeutics were worth $121,445,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in KYMR. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Kymera Therapeutics by 6.3% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,793 shares of the company’s stock valued at $849,000 after purchasing an additional 1,833 shares in the last quarter. Millennium Management LLC boosted its position in shares of Kymera Therapeutics by 340.4% during the 1st quarter. Millennium Management LLC now owns 510,480 shares of the company’s stock valued at $13,972,000 after purchasing an additional 394,562 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of Kymera Therapeutics by 121.5% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 896,404 shares of the company’s stock valued at $24,535,000 after purchasing an additional 491,737 shares in the last quarter. Invesco Ltd. boosted its position in shares of Kymera Therapeutics by 13.8% during the 2nd quarter. Invesco Ltd. now owns 47,884 shares of the company’s stock valued at $2,090,000 after purchasing an additional 5,809 shares in the last quarter. Finally, Sei Investments Co. purchased a new stake in Kymera Therapeutics during the second quarter valued at about $265,000.

Kymera Therapeutics Trading Down 0.2%

KYMR stock opened at $73.95 on Tuesday. Kymera Therapeutics, Inc. has a one year low of $36.65 and a one year high of $103.00. The firm has a market capitalization of $6.08 billion, a PE ratio of -20.71 and a beta of 2.02. The firm has a 50-day moving average of $82.88 and a two-hundred day moving average of $79.87.

Kymera Therapeutics (NASDAQ:KYMR) last posted its quarterly earnings results on Thursday, April 30th. The company reported ($0.71) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.89) by $0.18. The business had revenue of $34.37 million during the quarter, compared to analyst estimates of $8.27 million. Kymera Therapeutics had a negative net margin of 611.94% and a negative return on equity of 24.71%. The firm’s revenue was up 55.5% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.82) earnings per share. On average, equities research analysts anticipate that Kymera Therapeutics, Inc. will post -3.3 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. UBS Group upped their price objective on shares of Kymera Therapeutics from $90.00 to $128.00 and gave the company a “buy” rating in a research note on Tuesday, March 3rd. Wall Street Zen raised shares of Kymera Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 2nd. Citigroup upped their price objective on shares of Kymera Therapeutics from $110.00 to $120.00 and gave the company a “buy” rating in a research note on Monday, March 2nd. Canaccord Genuity Group assumed coverage on shares of Kymera Therapeutics in a research note on Wednesday, May 6th. They set a “buy” rating and a $106.00 price objective for the company. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating and set a $108.00 price objective on shares of Kymera Therapeutics in a research note on Thursday, February 26th. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $117.14.

Insiders Place Their Bets

In other news, CEO Nello Mainolfi sold 30,000 shares of the stock in a transaction that occurred on Wednesday, April 29th. The shares were sold at an average price of $81.18, for a total value of $2,435,400.00. Following the completion of the sale, the chief executive officer directly owned 666,195 shares of the company’s stock, valued at $54,081,710.10. This represents a 4.31% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Elena Ridloff sold 3,000 shares of the stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $87.00, for a total transaction of $261,000.00. Following the completion of the sale, the director directly owned 3,000 shares of the company’s stock, valued at $261,000. This trade represents a 50.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 260,115 shares of company stock valued at $21,218,138 over the last ninety days. Insiders own 15.98% of the company’s stock.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical?stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small?molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease?causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.